Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Elanco Animal Health IncorporatedNYSE: ELAN
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of $156M rose 22.8% year over year, ahead of the +12.7% change in trailing-twelve-month free cash flow. Sequentially, it fell 36.1% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.
Context
- Free cash flow amounted to 6.0% of revenue in FY2025, down 2.9 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +22.8% holds above the trailing-twelve-month pace of +12.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 284M USD
- Year-over-year change
- -27.9%
- 4-year CAGR
- -0.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 284M | -27.9% |
| FY2024 | 2024-12-31 | 394M | +236.8% |
| FY2023 | 2023-12-31 | 117M | -56.3% |
| FY2022 | 2022-12-31 | 268M | -6.3% |
| FY2021 | 2021-12-31 | 286M | — |
Free Cash Flow vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's LTM Sep 2026 free cash flow of $408M is the 4th largest of the 6 companies compared; the peer median is $1.3B.
- Its year-over-year change of +12.7% is the 3rd highest of 6, against a peer median of +9.1%.
- Free cash flow amounts to 7.9% of revenue for ELAN, versus a peer median of 24.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $16.06B | +9.1% | -5.6% | 24.2% | |
| LTM Jun 2026 | $2.37B | +6.6% | +19.9% | 24.9% | |
| LTM Sep 2026 | $1.3B | +36.3% | +38.8% | 27.9% | |
| LTM Sep 2026 | $408M | +12.7% | +2.0% | 7.9% | |
| LTM Aug 2026 | $49.75M | +1677.8% | — | 5.6% | |
| LTM Mar 2026 | $12.77M | -74.0% | — | 0.9% | |
| Peer median (excluding ELAN) | $1.3B | +9.1% | +19.9% | 24.2% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (472M) | (78M) | (1.23B) | 338M | (232M) |
| Depreciation & Amortization | 716M | 682M | 694M | 662M | 680M |
| Deferred Income Tax | (154M) | (57M) | (80M) | (112M) | (134M) |
| Stock-Based Compensation | 66M | 59M | 46M | 55M | 68M |
| Change in Working Capital | (87M) | (462M) | (300M) | 149M | 99M |
| Accounts Receivables | (3M) | 14M | (40M) | 12M | (12M) |
| Inventory | 27M | (269M) | (160M) | 44M | (57M) |
| Accounts Payables | (120M) | (98M) | (94M) | 82M | 147M |
| Other Working Capital | 9M | (109M) | (6M) | 11M | 21M |
| Other Non-Cash Items | 414M | 308M | 1.14B | (551M) | 79M |
| Operating Cash Flow | 483M | 452M | 271M | 541M | 560M |
| Capital Expenditures | (197M) | (184M) | (154M) | (147M) | (276M) |
| Acquisitions (Net) | (342M) | 13M | (19M) | 1.32B | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 9M | (8M) | (10M) | (14M) | (3M) |
| Investing Cash Flow | (530M) | (179M) | (169M) | 1.16B | (279M) |
| Debt Repayment | 177M | (517M) | (77M) | (1.48B) | (563M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33M | (32M) | (6M) | (17M) | 288M |
| Financing Cash Flow | 210M | (549M) | (83M) | (1.49B) | (275M) |
| Effect of Forex Changes | (31M) | (17M) | (12M) | (91M) | 71M |
| Net Change in Cash | 132M | (293M) | 7M | 116M | 77M |
| Free Cash Flow | 286M | 268M | 117M | 394M | 284M |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.